Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.5m USD

Relative Value

The Relative Value of one TSHA stock under the Base Case scenario is 2.85 USD. Compared to the current market price of 1.72 USD, Taysha Gene Therapies Inc is Undervalued by 40%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

TSHA Relative Value
Base Case
2.85 USD
Undervaluation 40%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
10
vs Industry
27
Median 3Y
24.3
Median 5Y
2.2
Industry
7.3
Forward
61.2
vs History
vs Industry
Median 3Y
-1.8
Median 5Y
-3.6
Industry
21.6
Forward
-4.4
vs History
vs Industry
Median 3Y
-3.8
Median 5Y
-4.7
Industry
19.8
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.9
Industry
24.9
vs History
29
vs Industry
11
Median 3Y
4.3
Median 5Y
4.1
Industry
2.4
vs History
14
vs Industry
26
Median 3Y
14.7
Median 5Y
1.4
Industry
7.4
Forward
44.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-2.7
Industry
3.9
Forward
-2.6
vs History
vs Industry
Median 3Y
-1.9
Median 5Y
-3
Industry
3.7
Forward
-2.6
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3.5
Industry
4.9
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3.5
Industry
3.2
vs History
38
vs Industry
15
Median 3Y
8.4
Median 5Y
10.3
Industry
4.3

Multiples Across Competitors

TSHA Competitors Multiples
Taysha Gene Therapies Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
352.5m USD 42.3 -3.9 -3 -3
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 464 388.3 -173 309.8 -210 453.3 -208 051.8
US
Abbvie Inc
NYSE:ABBV
373.8B USD 6.6 88.2 17.2 26
US
Amgen Inc
NASDAQ:AMGN
168.4B USD 5 41.2 16.6 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD 4.8 289.3 11.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD 11.8 -242.2 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 1 932 -493 -536.9 -522.5
AU
CSL Ltd
ASX:CSL
121.1B AUD 5 27.9 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD 5.1 16.6 10.9 12.2
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -57.1 -61.4 -55.4
NL
argenx SE
XBRU:ARGX
32.9B EUR 16.4 43 317.6 -2 339.6
P/S Multiple
Revenue Growth P/S to Growth
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average P/S: 3 315 130.6
42.3
75%
0.6
FR
Pharnext SCA
OTC:PNEXF
36 464 388.3
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.8
10%
1.2
US
E
Epizyme Inc
F:EPE
1 932
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.4
37%
0.4
P/E Multiple
Earnings Growth PEG
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average P/E: 84.4
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 309.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.2
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
289.3
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -493 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.1 N/A N/A
NL
argenx SE
XBRU:ARGX
43
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average EV/EBITDA: 59.6
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 453.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -536.9 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.4 N/A N/A
NL
argenx SE
XBRU:ARGX
317.6
168%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
Average EV/EBIT: 21.8
Negative Multiple: -3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 051.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -522.5 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 339.6 N/A N/A